GLOBAL OPHTHALMIC DRUGS MARKET 2019-2027

Lifesciences | Pharmaceuticals

GLOBAL OPHTHALMIC DRUGS MARKET 2019-2027

Market By Prescription Types, Therapeutics, End-users And Geography | Forecast 2019-2027

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

Triton predicts the global ophthalmic drugs market to rise in terms of revenue and grow at a CAGR of 4.47% from the forecast years 2019 to 2027. The market was assessed to be worth $26192.27 million in the year 2018 and is predicted to generate a revenue of approximately $38792.45 million by the year 2027.

Ophthalmic refers to the eye and the drugs designed to treat eye-related ailments are called ophthalmic drugs. The administration of the drug is done by the installation of an ointment, a cream or a liquid drop preparation in the conjunctival sac. The exact amount and strength of the drug are selected, and the medication is instilled into the eye or eyes as directed. Ophthalmic drugs are widely used to treat conditions like cataracts, glaucoma, diabetic retinopathy, and other ophthalmic disorders. The pioneering of novel ocular drug delivery approaches in the market has encouraged the manufacturers to develop innovative therapeutic approaches for the treatment of ophthalmic disorders.

Report scope can be customized per your requirements. Request For Customization

Ophthalmic drugs therapeutics are used extensively for various purposes. Diabetic macular edema (abbreviated as DME) refers to the thickening of the retina within the two-disc diameters of the center of the macula, which primarily occurs from the changes in the retinal microvascular that is compromised of the blood-retinal barrier. Eye cancer can be referred to as the growth of the abnormal cells inside or around the eye that leads to the development of a tumor within the eye. 

Diabetic retinopathy can be referred to as a diabetic complication that affects the eyesight of the individuals. Diabetic retinopathy affects the blood vessels inside the retina. Retinal vein blockage may be defined as a small vein’s blockage that executes the function of carrying out blood from the retina. Age-related macular degeneration is one of the most common eye conditions and the primary cause of vision loss among the population aged 50 and above. 

Conjunctivitis, referred to as “pink eye” may be defined as the inflammation of the conjunctiva; the conjunctiva is a thin & transparent layer that covers the inside of the eyelids and the white part of the eye. Dry eye occurs when tears are not of exact consistency or when the eyes do not produce tears correctly and evaporate too fast. Glaucoma can be referred to as the group of eye diseases that damage the optic nerve, and that leads to vision loss. Keratitis is the inflammation of the cornea. Geographic atrophy (GA) is the advanced form of dry age-related macular degeneration (AMD).

The Triton report on the ophthalmic drugs market has discussed the value chain outlook, the key insights regarding the industry, Porter’s five force analysis, and the vendor scorecard.

Market drivers such as the advancement in technology, the growing geriatric population worldwide, rising expenditure in healthcare and the rising occurrence of eye syndromes are advancing the market growth globally. However, restraints like delays in drug approvals and brand patent expirations are expected to create hurdles in the growth of the market. The rise in the rates of ophthalmic treatments and emerging economies are creating opportunities for the market to grow in the projected period.

To get detailed insights on segments, Download Sample Report

Geographies that have been covered in the global ophthalmic drugs market are:

•    North America: the United States and Canada

•    Europe: the United Kingdom, Germany, France, Italy, Spain, Russia.

•    Asia-Pacific: China, Japan, India, South Korea, ASEAN countries, Australia & New Zealand.

•    Latin America: Brazil, Mexico and Rest of Latin America

•    The Middle East & Africa: the United Arab Emirates, Turkey, Saudi Arabia, South Africa and Rest of the Middle East & Africa

The ophthalmic drugs market has been segmented into:

•    By prescription type:

O    Prescription ophthalmic drugs

O    OTC (Over-the-Counter) drugs

•    By therapeutics:

O    Diabetic macular edema

O    Eye cancer

O    Diabetic retinopathy

O    Retinal vein occlusion

O    Age-related macular degeneration

O    Conjunctivitis

O    Dry eye

O    Glaucoma

O    Keratitis

O    Geographic Atrophy

O    Lens opacification and intraocular lens

•    By End-Users: 

O    Hospitals

O    Eye clinics ophthalmic drugs

O    Diagnostics centers ophthalmic drugs

O    Patient ophthalmic drugs

The key players in the ophthalmic drugs market include Santen Pharmaceutical Co., Ltd, SENJU Pharmaceutical Co., Ltd, Roche Holding AG, Abbott Laboratories, GlaxoSmithKline, Allergan, Inc., Cipla Pharmaceuticals, Sun Pharmaceuticals Industries, Ltd., Pfizer, Inc., EyeGate Pharmaceuticals, Merck & Co., Johnson and Johnson, EyeMed, Regeneron, Valeant, Novartis AG, Apollo Endosurgery, Akorn and Bayer.

The strategic analysis for each of the companies in the ophthalmic drugs market is detailed in the report. The company market share helps with the information of the key market players and their share in the market.

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1.    GLOBAL OPHTHALMIC DRUGS MARKET - SUMMARY

2.    INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. VALUE CHAIN OUTLOOK

2.3. VENDOR SCORECARD

2.4. KEY INSIGHTS

2.5. PORTER’S FIVE FORCES OUTLOOK

2.5.1.   BARGAINING POWER OF BUYERS

2.5.2.   BARGAINING POWER OF SUPPLIER

2.5.3.   THREATS OF NEW ENTRANTS

2.5.4.   THREATS OF SUBSTITUTES

2.5.5.   COMPETITIVE RIVALRY

2.6. MARKET DRIVERS

2.6.1.   ADVANCEMENT IN TECHNOLOGY

2.6.2.   GROWING GERIATRIC POPULACE WORLDWIDE

2.6.3.   RISING EXPENDITURE IN HEALTHCARE

2.6.4.   RISING OCCURRENCE OF EYE SYNDROMES

2.7. MARKET RESTRAINTS

2.7.1.   DELAY IN DRUG APPROVALS

2.7.2.   BRAND PATENT EXPIRATIONS

2.8. MARKET OPPORTUNITIES

2.8.1.   RISE IN THE RATES OF OPHTHALMIC TREATMENT

2.8.2.   RISING OPPORTUNITIES IN EMERGING ECONOMIES

3.    OPHTHALMIC DRUGS MARKET OUTLOOK – BY PRESCRIPTION TYPES

3.1. PRESCRIPTION OPHTHALMIC DRUGS

3.2. OTC (OVER-THE-COUNTER DRUGS)

4.    OPHTHALMIC DRUGS MARKET OUTLOOK – BY THERAPEUTICS

4.1. DIABETIC MACULAR EDEMA

4.2. EYE CANCER

4.3. DIABETIC RETINOPATHY

4.4. RETINAL VEIN OCCLUSION

4.5. AGE-RELATED MACULAR DEGENERATION

4.6. CONJUNCTIVITIS

4.7. DRY EYE

4.8. GLAUCOMA

4.9. KERATITIS

4.10.            GEOGRAPHIC ATROPHY

4.11.            LENS OPACIFICATION AND INTRAOCULAR LENS

5.    OPHTHALMIC DRUGS MARKET OUTLOOK – BY END-USERS

5.1. HOSPITALS

5.2. EYE CLINICS OPHTHALMIC DRUGS

5.3. DIAGNOSTIC CENTERS OPHTHALMIC DRUGS

5.4. PATIENT OPHTHALMIC DRUGS

6.    OPHTHALMIC DRUGS MARKET – REGIONAL OUTLOOK

6.1. NORTH AMERICA

6.1.1.   COUNTRY ANALYSIS

6.1.1.1.      UNITED STATES

6.1.1.2.      CANADA

6.2. EUROPE

6.2.1.   COUNTRY ANALYSIS

6.2.1.1.      GERMANY

6.2.1.2.      UNITED KINGDOM

6.2.1.3.      RUSSIA

6.2.1.4.      FRANCE

6.2.1.5.      ITALY

6.2.1.6.      SPAIN

6.3. ASIA-PACIFIC

6.3.1.   COUNTRY ANALYSIS

6.3.1.1.      CHINA

6.3.1.2.      INDIA

6.3.1.3.      SOUTH KOREA

6.3.1.4.      JAPAN

6.3.1.5.      AUSTRALIA & NEW ZEALAND

6.3.1.6.      ASEAN COUNTRIES

6.4. MIDDLE EAST & AFRICA

6.4.1.   COUNTRY ANALYSIS

6.4.1.1.      SAUDI ARABIA

6.4.1.2.      TURKEY

6.4.1.3.      UNITED ARAB EMIRATES

6.4.1.4.      SOUTH AFRICA

6.4.1.5.      REST OF MIDDLE EAST & AFRICA

6.5. LATIN AMERICA

6.5.1.   COUNTRY ANALYSIS

6.5.1.1.      MEXICO

6.5.1.2.      BRAZIL

6.5.1.3.      REST OF LATIN AMERICA

7.    COMPETITIVE LANDSCAPE

7.1. ABBOTT LABORATORIES

7.2. JOHNSON AND JOHNSON

7.3. ALLERGAN, INC.

7.4. BAYER

7.5. REGENERON

7.6. AKORN

7.7. VALEANT

7.8. EYEMED

7.9. SENJU PHARMACEUTICAL CO., LTD

7.10.            MERCK & CO.

7.11.            PFIZER, INC.

7.12.            NOVARTIS AG

7.13.            GLAXOSMITHKLINE

7.14.            EYEGATE PHARMACEUTICALS

7.15.            ROCHE HOLDING AG

7.16.            APOLLO ENDOSURGERY

7.17.            SANTEN PHARMACEUTICAL CO., LTD

7.18.            SUN PHARMACEUTICALS INDUSTRIES, LTD.

7.19.            CIPLA PHARMACEUTICALS

8.    METHODOLOGY AND SCOPE

8.1. RESEARCH SCOPE

8.2. SOURCES OF DATA

8.3. RESEARCH METHODOLOGY

List of table

TABLE 1        GLOBAL OPHTHALMIC DRUGS MARKET BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE 2        COMMON CAUSES OF LOSS OF VISION IN THE ELDERLY

TABLE 3        EYE DRUGS GONE OFF-PATENT

TABLE 4        GLOBAL OPHTHALMIC DRUGS MARKET BY PRESCRIPTION TYPE 2019-2027 ($ MILLION)

TABLE 5        FDA-APPROVED DRUGS FOR OPHTHALMOLOGY

TABLE 6        DETAILS OF SOME KEY PRESCRIPTION DRUGS

TABLE 7        OPHTHALMIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE

TABLE 8        GLOBAL OPHTHALMIC DRUGS MARKET BY THERAPEUTICS 2019-2027 ($ MILLION)

TABLE 9        SYMPTOMS, TREATMENT AND RECOVERY TIME FOR DIABETIC MACULAR EDEMA

TABLE 10      SYMPTOMS AND TREATMENT FOR EYE CANCER

TABLE 11      GLOBAL OPHTHALMIC DRUGS MARKET BY END-USERS 2019-2027 ($ MILLION)

TABLE 12      GLOBAL OPHTHALMIC DRUGS MARKET BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE 13      NORTH AMERICA OPHTHALMIC DRUGS MARKET BY COUNTRIES 2019-2027 ($ MILLION)

TABLE 14      UNITED STATES OPHTHALMIC DRUGS MARKET BY END-USERS 2019-2027 ($ MILLION)

TABLE 15      UNITED STATES HOSPITAL FACT SHEET, 2016

TABLE 16      CANADA OPHTHALMIC DRUGS MARKET BY END-USERS 2019-2027 ($ MILLION)

TABLE 17      EXTRAPOLATION OF PREVALENCE RATE OF GLAUCOMA BY COUNTRIES

TABLE 18      EUROPE OPHTHALMIC DRUGS MARKET BY COUNTRIES 2019-2027 ($ MILLION)

TABLE 19      GERMANY OPHTHALMIC DRUGS MARKET BY END-USERS 2019-2027 ($ MILLION)

TABLE 20      UK OPHTHALMIC DRUGS MARKET BY END-USERS 2019-2027 ($ MILLION)

TABLE 21      RUSSIA OPHTHALMIC DRUGS MARKET BY END-USERS 2019-2027 ($ MILLION)

TABLE 22      NUMBER OF HOSPITALS IN RUSSIA, 2015

TABLE 23      FRANCE OPHTHALMIC DRUGS MARKET BY END-USERS 2019-2027 ($ MILLION)

TABLE 24      ITALY OPHTHALMIC DRUGS MARKET BY END-USERS 2019-2027 ($ MILLION)

TABLE 25      SPAIN OPHTHALMIC DRUGS MARKET BY END-USERS 2019-2027 ($ MILLION)

TABLE 26      ASIA-PACIFIC OPHTHALMIC DRUGS MARKET BY COUNTRIES 2019-2027 ($ MILLION)

TABLE 27      CHINA OPHTHALMIC DRUGS MARKET BY END-USERS 2019-2027 ($ MILLION)

TABLE 28      INDIA OPHTHALMIC DRUGS MARKET BY END-USERS 2019-2027 ($ MILLION)

TABLE 29      HUMAN RESOURCE NEEDS FOR EYE CARE IN INDIA

TABLE 30      SOUTH KOREA OPHTHALMIC DRUGS MARKET BY END-USERS 2019-2027 ($ MILLION)

TABLE 31      JAPAN OPHTHALMIC DRUGS MARKET BY END-USERS 2019-2027 ($ MILLION)

TABLE 32      AUSTRALIA & NEW ZEALAND OPHTHALMIC DRUGS MARKET BY END-USERS 2019-2027 ($ MILLION)

TABLE 33      MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET BY COUNTRIES 2019-2027 ($ MILLION)

TABLE 34      MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET BY END-USERS 2019-2027 ($ MILLION)

TABLE 35      LATIN AMERICA OPHTHALMIC DRUGS MARKET BY COUNTRIES 2019-2027 ($ MILLION)

TABLE 36      LATIN AMERICA OPHTHALMIC DRUGS MARKET BY END-USERS 2019-2027 ($ MILLION)

TABLE 37      MEXICO OPHTHALMIC DRUGS MARKET BY END-USERS 2019-2027 ($ MILLION)

List of Figures

FIGURE 1      THE POPULATION OF PEOPLE AGED 65 AND OVER WILL DOUBLE IN THE NEXT 25 YEARS (MILLION)

FIGURE 2      PROJECTIONS FOR THE PROPORTION OF GERIATRIC (60+) POPULATION IN 2015, 2030 AND 2050

FIGURE 3      HEALTHCARE EXPENDITURE CATARACT SURGERIES ON THE RISE

FIGURE 4      WORLDWIDE PREVALENCE OF PRESBYOPIA 2015, 2020 AND 2050 (MILLION)

FIGURE 5      PREVALENCE OF GLAUCOMA AT GLOBAL LEVEL IN 2013, 2020 AND 2040 (MILLION)

FIGURE 6      GLOBAL OPHTHALMIC DRUGS MARKET IN PRESCRIPTION OPHTHALMIC DRUGS 2019-2027 ($ MILLION)

FIGURE 7      GLOBAL OPHTHALMIC DRUGS MARKET IN OTC 2019-2027 ($ MILLION)

FIGURE 8      GLOBAL OPHTHALMIC DRUGS MARKET IN DIABETIC MACULAR EDEMA 2019-2027 ($ MILLION)

FIGURE 9      GLOBAL OPHTHALMIC DRUGS MARKET IN EYE CANCER 2019-2027 ($ MILLION)

FIGURE 10   DIABETIC RETINOPATHY PREVALENCE IN THE US 2011 AND 2030 (MILLION)

FIGURE 11   GLOBAL OPHTHALMIC DRUGS MARKET IN DIABETIC RETINOPATHY 2019-2027 ($ MILLION)

FIGURE 12   GLOBAL OPHTHALMIC DRUGS MARKET IN RETINAL VEIN OCCLUSION 2019-2027 ($ MILLION)

FIGURE 13   GLOBAL OPHTHALMIC DRUGS MARKET IN AGE-RELATED MACULAR DEGENERATION 2019-2027 ($ MILLION)

FIGURE 14   GLOBAL OPHTHALMIC DRUGS MARKET IN CONJUNCTIVITIS 2019-2027 ($ MILLION)

FIGURE 15   GLOBAL OPHTHALMIC DRUGS MARKET IN DRY EYE 2019-2027 ($ MILLION)

FIGURE 16   GLOBAL OPHTHALMIC DRUGS MARKET IN GLAUCOMA THERAPEUTICS 2019-2027 ($ MILLION)

FIGURE 17   GLOBAL OPHTHALMIC DRUGS MARKET IN KERATITIS 2019-2027 ($ MILLION)

FIGURE 18   GLOBAL OPHTHALMIC DRUGS MARKET IN GEOGRAPHIC ATROPHY 2019-2027 ($ MILLION)

FIGURE 19   GLOBAL OPHTHALMIC DRUGS MARKET IN LENS OPACIFICATION AND INTRAOCULAR LENS 2019-2027 ($ MILLION)

FIGURE 20   GLOBAL OPHTHALMIC DRUGS MARKET IN HOSPITALS OPHTHALMIC DRUGS 2019-2027 ($ MILLION)

FIGURE 21   TOTAL OPHTHALMIC CARE HOSPITAL IN UNITED STATES

FIGURE 22   GLOBAL OPHTHALMIC DRUGS MARKET IN EYE CLINICS OPHTHALMIC DRUGS 2019-2027 ($ MILLION)

FIGURE 23   EYE DISEASES CASES IN MILLION ABOVE AGE OF 40 IN AMERICA

FIGURE 24   GLOBAL OPHTHALMIC DRUGS MARKET IN DIAGNOSTIC CENTERS OPHTHALMIC DRUGS 2019-2027 ($ MILLION)

FIGURE 25   TOTAL VISUAL IMPAIRMENT AND BLINDNESS CASES ABOVE AGE 40 IN US (IN MILLION)

FIGURE 26   GLOBAL OPHTHALMIC DRUGS MARKET IN PATIENTS OPHTHALMIC DRUGS 2019-2027 ($ MILLION)

FIGURE 27   NORTH AMERICA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 28   US POPULATION AGES 65 AND OLDER, 1960 TO 2060 (MILLION)

FIGURE 29   US OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 30   CANADA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 31   PREVALENCE RATE OF RETINAL DISORDERS IN CANADA, 2016

FIGURE 32   FINANCIAL COST SHARE OF RETINA DISORDER TREATMENT IN CANADA

FIGURE 33   EUROPE OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 34   DEVELOPMENT OF THE EUROPEAN POPULATION AGED 65 AND OVER, 2010, 2025 AND 2050 (MILLION)

FIGURE 35   PROPORTION OF OPTOMETRISTS AND OPTICIANS IN EUROPEAN COUNTRIES, 2015

FIGURE 36   GERMANY OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 37   POPULATION AGES 65 AND ABOVE (% OF TOTAL)

FIGURE 38   UK OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 39   PROJECTED NUMBER OF PEOPLE LIVING WITH SIGHT LOSS IN THE UK (MILLION)

FIGURE 40   RUSSIA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 41   POPULATION AGED 65 AND ABOVE IN FRANCE (% OF TOTAL)

FIGURE 42   FRANCE OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 43   POPULATION AGED 65 AND ABOVE IN ITALY (% OF TOTAL)

FIGURE 44   ITALY OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 45   POPULATION AGED 65 AND ABOVE IN SPAIN (% OF TOTAL)

FIGURE 46   SPAIN OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 47   ASIA-PACIFIC OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 48   CHINA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 49   INDIA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 50   SOUTH KOREA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 51   NUMBER OF YEARS FOR PERCENTAGE, AGED 65 AND ABOVE IN TOTAL POPULATION TO TRIPLE

FIGURE 52   POPULATION AGED 65 AND ABOVE IN JAPAN (% OF TOTAL)

FIGURE 53   JAPAN OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 54   POPULATION AGED 65 AND ABOVE IN AUSTRALIA (% OF TOTAL)

FIGURE 55   AUSTRALIA AND NEW ZEALAND OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 56   ASEAN COUNTRIES OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 57   MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 58   SAUDI ARABIA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 59   TURKEY OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 60   UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 61   SOUTH AFRICA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 62   REST OF MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 63   LATIN AMERICA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 64   AGING POPULATION IN COLOMBIA 1950-2050 (IN THOUSANDS)

FIGURE 65   MEXICO OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 66   PERCENTAGE OF PEOPLE AGED 65 AND ABOVE, MEXICO (1950-2050)

FIGURE 67   PROPORTION OF DIRECT COST OF EYE DISEASE IN MEXICO, BY PAYER

FIGURE 68   BRAZIL OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE 69   REST OF LATIN AMERICA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$2,750.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$4,000.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;